Business
Apyx Medical Corporation Announces New Additions to Clinical and Regulatory Affairs Teams
Kari Larson Appointed as Senior Director of Clinical Studies; Libet Garber, Ph.D. Appointed as Global Director of Regulatory Affairs CLEARWATER,
About this update from Apyx Medical Corporation
[{"type":"text","content":"\nKari Larson Appointed as Senior Director of Clinical Studies; Libet Garber, Ph.D. Appointed as Global Director of Regulatory Affairs\n\n CLEARWATER, Fla.--(BUSINESS WIRE)--\n\nApyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, which is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that the company has enhanced its clinical and regulatory affairs teams with the appointment of Kari Larson and Libet Garber, Ph.D. to the positions of Senior Director of Clinical Affairs and Director of Global Regulatory Affairs, respectively.\n\n\n“I’m very pleased to welcome Ms. Kari Larson and Dr. Libet Garber to our clinical and regulatory affairs teams as they assume these newly created leadership positions,” said Charlie Goodwin, Chief Executive Officer. “Libet and Kari are both highly experienced professionals, and we hope to leverage their strategic insight and leadership capabilities as we evaluate and pursue new specific clinical indications enabling us to market and sell Renuvion for our target procedures and secure additional clinical evidence demonstrating the safety and effectiveness of our Renuvion technology in the cosmetic surgery market.”\n\n\nKari Larson - Senior Director of Clinical Affairs:\n\n\nMs. Larson joins Apyx Medical with over 15 years of clinical research experience at both healthcare companies and clinical sites. Prior to joining Apyx Medical, Ms. Larson was the Director of Clinical Research for Lutronic Global from 2017 until 2019 where she was responsible for the execution and management of the company’s U.S. clinical trials. Lutronic Global is a division of Lutronic Corp., a global aesthetic laser company based in Korea and listed on the KOSDAQ. From 2011 until 2017, she was the Senior Director of Clinical Affairs for Ulthera, Inc. which was acquired during her tenure by Merz North America, Inc., a Raleigh, North Carolina based healthcare company focused on the aesthetics market. While at Merz/Ulthera, she was instrumental in achieving soft tissue lifting claims with the FDA for the Ultherapy System. From 2008 until 2011, Ms. Larson was a Manager of Clinical Applications & Education for Myoscience, Inc., a priva...